Taking a closer look - Oral Anticoagulants


  • Oral anticoagulant are utilized in treatment of many cardiovascular indications like NAVF, AF, DVT, PE and stroke.
  • Warfarin and Apixaban are most recommended treatments and Pfizer, Novartis, Bayer and Merck are the biggest players in the space. The key considerations that influences therapy choice are efficacy, safety, frequency of monitoring and cost of the drug.
  • The most important unmet medical needs in the space are gaps in diagnosis and optimizing quick diagnosis, Delays in treatment start due to long waiting time for specialists appointment, and low drug adherence.
  • To address the unmet needs pharma companies, regulatory bodies are undertaking many initiatives including digitalization, implementing AI in diagnosis equipment etc.

Oral anticoagulant like warfarin, NOACs are utilized in treatment of many cardiovascular indications like NAVF, AF, DVT, PE and stroke. Patients seek medical attention from GPs or Specialist due to pre-existing illness. Most common symptoms of NVAF patients are high blood pressure, Chest pain, irregular heartbeats and shortness of breath; and most common symptoms of DVT patients are pain, swelling and clot in legs.

For diagnosis the basic tests conducted are ECG, Blood tests, blood pressure tests and ultrasound, as per the set protocol of Hospitals followed by GPs and Specialists. Warfarin and Apixaban are most recommended treatments and Pfizer, Novartis, Bayer and Merck are the biggest players in the space. The key considerations that influences therapy choice are efficacy, safety, frequency of monitoring and cost of the drug.

We think that the most important unmet medical needs in the space are gaps in diagnosis and optimizing quick diagnosis, Delays in treatment start due to long waiting time for specialists appointment, gaps in effective communication between Physicians and Specialists, lack of awareness, lack of manpower, Lack of advanced diagnostic tools, and low drug adherence.

To address the needs regulatory bodies, Pharma companies and patient associations have undertaken many initiatives which involves digitalization (e.g., mobile apps), educating patients via seminars, campaigns and raising awareness at national, regional and local level and implying conventional methods like enhancing effective communication through electronic medium and implementing anti-coagulation alert cards etc.

We think that smooth collaboration between the primary and the secondary care to avoid delay in referral and treatment start, thereby speeding up the process of screening and hence preventing the risk of stroke can be one of the most important futuristic approach to improve quality of care. Others can be using Application based diagnostic tools or devices or Advanced technology like mobile app, wearables, powerful ultrasounds, X-ray or body scanners that can improve patient outcomes and patient care management by improving testing, diagnosis, providing quick results and enhancing drug adherence.

Application enabling initial screening of the patients with AF on the basis of age or prevailing medical condition. Artificial intelligence incorporated in the diagnosis equipment for analyzing the condition with minimum artifacts and accurate results can also help in improving patient outcome